HCA Falls After 2026 Guidance Cut Tied to Exchange Coverage Losses

HCA Healthcare (HCA) is down 7.3% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely catalyst is a fresh cut to HCA’s 2026 outlook after the company said more patients are losing health insurance coverage through federal and state exchanges, which is pushing its payer mix toward more uninsured care. That appears to have amplified existing investor concerns around policy-driven coverage losses, softer reimbursement mix, and pressure on Medicaid-related supplemental payments.

Details:

HCA lowered its full-year 2026 guidance on July 14, trimming its revenue, net income, diluted EPS, and adjusted EBITDA outlook ranges.

The company said second-quarter results were hurt by a shift toward increased uninsured volume, primarily tied to patients who lost exchange coverage, with an estimated unfavorable impact of about $400 million on income before taxes.

HCA also increased its estimate for the 2026 exchange-related headwind to roughly $1.0 billion to $1.2 billion, up from its earlier $600 million to $900 million range.

Earlier company filings had already warned that exchange reforms, the expiration of enhanced premium tax credits, and lower supplemental payment revenue could weigh on 2026, while a recent analyst downgrade added to concerns about volumes, payor mix, and Medicaid cuts.

Sources:

HCA Healthcare Investor Relations, SEC, TipRanks, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$HCA Insider Trading Activity

$HCA insiders have traded $HCA stock on the open market 12 times in the past 6 months. Of those trades, 0 have been purchases and 12 have been sales.

Here’s a breakdown of recent trading of $HCA stock by insiders over the last 6 months:

SAMUEL N HAZEN (CEO) has made 0 purchases and 7 sales selling 42,877 shares for an estimated $21,483,274.
JENNIFER BERRES (SVP & Chief Human Res. Officer) has made 0 purchases and 2 sales selling 8,020 shares for an estimated $4,126,950.
CHRISTOPHER F. WYATT (SVP & Controller) sold 4,000 shares for an estimated $2,020,000
MICHAEL R MCALEVEY (EVP & Chief Legal & Admin Off.) sold 1,694 shares for an estimated $903,536
MICHAEL S. CUFFE (EVP and Chief Clinical Officer) sold 1,500 shares for an estimated $747,135

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$HCA Hedge Fund Activity

We have seen 521 institutional investors add shares of $HCA stock to their portfolio, and 640 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CAPITAL INTERNATIONAL INVESTORS added 3,033,612 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,435,626,542
CAPITAL WORLD INVESTORS removed 3,026,993 shares (-60.5%) from their portfolio in Q1 2026, for an estimated $1,432,494,167
SANDERS CAPITAL, LLC removed 1,507,023 shares (-14.4%) from their portfolio in Q1 2026, for an estimated $713,183,564
BLACKROCK, INC. added 782,179 shares (+6.2%) to their portfolio in Q1 2026, for an estimated $370,158,389
NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO removed 647,721 shares (-97.6%) from their portfolio in Q1 2026, for an estimated $306,527,486
FMR LLC added 567,650 shares (+14.8%) to their portfolio in Q1 2026, for an estimated $268,634,686
WELLINGTON MANAGEMENT GROUP LLP added 483,726 shares (+14.1%) to their portfolio in Q1 2026, for an estimated $228,918,492

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$HCA Analyst Ratings

Wall Street analysts have issued reports on $HCA in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Oppenheimer issued a "Outperform" rating on 01/28/2026
Truist Securities issued a "Buy" rating on 01/28/2026
Deutsche Bank issued a "Buy" rating on 01/28/2026
Barclays issued a "Overweight" rating on 01/28/2026
Jefferies issued a "Buy" rating on 01/28/2026

To track analyst ratings and price targets for $HCA, check out Quiver Quantitative's $HCA forecast page.

$HCA Price Targets

Multiple analysts have issued price targets for $HCA recently. We have seen 16 analysts offer price targets for $HCA in the last 6 months, with a median target of $532.0.

Here are some recent targets:

Andrew Mok from Barclays set a target price of $427.0 on 07/08/2026
Sarah James from Cantor Fitzgerald set a target price of $525.0 on 07/07/2026
Ryan Langston from TD Cowen set a target price of $431.0 on 06/22/2026
Lance Wilkes from Bernstein set a target price of $413.0 on 06/04/2026
David Macdonald from Truist Securities set a target price of $535.0 on 04/27/2026
Matthew Gillmor from Keybanc set a target price of $510.0 on 04/27/2026
Michael Wiederhorn from Oppenheimer set a target price of $520.0 on 04/27/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.